55 y/o M with favorable intermediate risk prostate adenocarcinoma (cT1cN0M0, Gleason 3+4, PSA 9, 5/12 cores involved bilaterally).
TECHNIQUE:
DOSE: He received 3625cGy with 6MV photons delivered every other day.
SIMULATION: He was simulated supine with a comfortably full bladder and empty rectum in a vac-lock bag. MR simulation or fusion of diagnostic MRI will also assist in target and OAR delineation.
Case contributed by Leonid Reshko from the University of Louisville
RT coverage (per NRG GU-005 protocol):
OAR delineation:
Prostate SBRT is currently recommended as monotherapy for patients with low and favorable intermediate risk prostate cancer, per Jackson et al. IJROBP 2019. Ongoing prospective trials such as NRG GU-005 and HEAT are assessing non-inferiority of prostate SBRT vs moderately hypofractionated RT.
OAR Constraints (ideal – variable acceptable):
Questions? Feedback? Report here